Enalapril
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| ACE Inhibitors | Enalapril | 2.5-10mg PO Q24-48H | Administer Post HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 376 | 88 | 11-24 | 34-60 | 50-60 | 1-2.4 | 38.8-42 | 38-57 (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00584
- Inrig J. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010; 23(3):290-7.
- Kelly J, Doyle G, Carmody M, Glover D, Cooper W. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis. British journal of clinical pharmacology. 1988; 26(6):781-6.
- Tsuruoka S, Kitoh Y, Kawaguchi A, et al. Clearance of imidapril, an Angiotensin-converting enzyme inhibitor, during hemodialysis in hypertensive renal failure patients: comparison with quinapril and enalapril. Journal of clinical pharmacology. 2007; 47(2):259-63.
- Zheng S, Nath V, Coyne D. ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. American journal of nephrology. 2007; 27(5):522-9.